Realbotix Announces Brokered Life Offering of up to C$5,000,000


This news release contains forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”) that relate to Realbotix’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, “projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the completion of the Offering, approvals of the TSXV, the issuance of the Units, the intended use of the net proceeds from the Offering and the expected closing date of the Offering. The Company believes that the expectations reflected in those forward-looking statements are reasonable but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.



Source link

  • Related Posts

    Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan

    PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve…

    Novartis expects low single-digit decline in 2026 operating profit

    FRANKFURT, Feb 4 (Reuters) – Swiss drugmaker Novartis forecast a decline in ​2026 operating profit in the low ‌single-digit percentage range on Wednesday, held back ‌by competition from cheaper copies…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Kris Van Assche Has Done a Collaboration with Fred Perry

    Kris Van Assche Has Done a Collaboration with Fred Perry

    Nate Horner publishes perennial Alberta poverty plea, warns of ‘tough choices’

    Nate Horner publishes perennial Alberta poverty plea, warns of ‘tough choices’

    Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan

    Fairphone 6 review: cheaper, repairable and longer-lasting Android | Smartphones

    Fairphone 6 review: cheaper, repairable and longer-lasting Android | Smartphones

    Good news, Stardew Valley enthusiasts: the 1.7 update will make children ‘a little more interesting’ and add two new marriage candidates

    Good news, Stardew Valley enthusiasts: the 1.7 update will make children ‘a little more interesting’ and add two new marriage candidates

    Jaren Jackson Jr. trade grades: Why Grizzlies earn slightly better mark than Jazz

    Jaren Jackson Jr. trade grades: Why Grizzlies earn slightly better mark than Jazz